Neurology:帕金森患者护理的性别差异

2017-12-03 zhangfan MedSci原创

研究认为,帕金森女性患者需要陪护的比例低于男性患者,且病情护理负担较低,但女性帕金森患者使用专业有偿陪护的意愿高于男性患者

近日研究人员考察了影响帕金森患者护理的性别因素。

研究于2009-14年间在21个中心开展。研究的主要终点是帕金森患者的首次入院检查,通过多维护理应变指数(MCSI)考察患者帕金森病情护理负担,记录患者首次入院治疗的年龄。

总计7209名帕金森患者参与评估,其中男性患者占63%,男性患者首次入院年龄66.0岁,女性患者66.9岁。男性患者需要贴身护理的比例较高(88.4% vs 79.4%, p < 0.0001),且护理负担高于女性患者(MCSI分数 19.9 vs 16.4, p < 0.0001),该差异在调整年龄、疾病阶段、合并症、认知和行动以及与健康相关的生活质量后仍持续存在。患者基线时,女性需要有偿陪护的比例低于男性(OR 0.76, 95% CI 0.67–0.86),但女性患者因疾病进展需要有偿陪护的意愿高于男性(HR1.76, 95% CI 1.35–2.28)。

研究认为,帕金森女性患者需要陪护的比例低于男性患者,且病情护理负担较低,但女性帕金森患者使用专业有偿陪护的意愿高于男性患者。

原始出处:

Nabila Dahodwala et al. Sex disparities in access to caregiving in Parkinson disease. Neurology. December 01 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000205, encodeId=bf7d200020535, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat May 19 12:18:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267206, encodeId=5cea26e206fe, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed Dec 06 08:59:53 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266667, encodeId=b28e26666ef9, content=喜欢喜欢不想继续, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHmiaPStHsBjHGm3Y4ZHHanFXRDgAiaEiabOGdC4Q6KfAYrmmuicVyBk7YMJOMXTuQnIpZqReTiceibjdg/132, createdBy=2ab92087896, createdName=陈方郑, createdTime=Mon Dec 04 08:10:19 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266399, encodeId=e23926639950, content=学习好的好好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHmiaPStHsBjHGm3Y4ZHHanFXRDgAiaEiabOGdC4Q6KfAYrmmuicVyBk7YMJOMXTuQnIpZqReTiceibjdg/132, createdBy=2ab92087896, createdName=陈方郑, createdTime=Sun Dec 03 08:23:42 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2018-05-19 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000205, encodeId=bf7d200020535, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat May 19 12:18:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267206, encodeId=5cea26e206fe, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed Dec 06 08:59:53 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266667, encodeId=b28e26666ef9, content=喜欢喜欢不想继续, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHmiaPStHsBjHGm3Y4ZHHanFXRDgAiaEiabOGdC4Q6KfAYrmmuicVyBk7YMJOMXTuQnIpZqReTiceibjdg/132, createdBy=2ab92087896, createdName=陈方郑, createdTime=Mon Dec 04 08:10:19 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266399, encodeId=e23926639950, content=学习好的好好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHmiaPStHsBjHGm3Y4ZHHanFXRDgAiaEiabOGdC4Q6KfAYrmmuicVyBk7YMJOMXTuQnIpZqReTiceibjdg/132, createdBy=2ab92087896, createdName=陈方郑, createdTime=Sun Dec 03 08:23:42 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-06 半夏微凉

    学习了谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2000205, encodeId=bf7d200020535, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat May 19 12:18:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267206, encodeId=5cea26e206fe, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed Dec 06 08:59:53 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266667, encodeId=b28e26666ef9, content=喜欢喜欢不想继续, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHmiaPStHsBjHGm3Y4ZHHanFXRDgAiaEiabOGdC4Q6KfAYrmmuicVyBk7YMJOMXTuQnIpZqReTiceibjdg/132, createdBy=2ab92087896, createdName=陈方郑, createdTime=Mon Dec 04 08:10:19 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266399, encodeId=e23926639950, content=学习好的好好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHmiaPStHsBjHGm3Y4ZHHanFXRDgAiaEiabOGdC4Q6KfAYrmmuicVyBk7YMJOMXTuQnIpZqReTiceibjdg/132, createdBy=2ab92087896, createdName=陈方郑, createdTime=Sun Dec 03 08:23:42 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-04 陈方郑

    喜欢喜欢不想继续

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2000205, encodeId=bf7d200020535, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat May 19 12:18:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267206, encodeId=5cea26e206fe, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed Dec 06 08:59:53 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266667, encodeId=b28e26666ef9, content=喜欢喜欢不想继续, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHmiaPStHsBjHGm3Y4ZHHanFXRDgAiaEiabOGdC4Q6KfAYrmmuicVyBk7YMJOMXTuQnIpZqReTiceibjdg/132, createdBy=2ab92087896, createdName=陈方郑, createdTime=Mon Dec 04 08:10:19 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266399, encodeId=e23926639950, content=学习好的好好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHmiaPStHsBjHGm3Y4ZHHanFXRDgAiaEiabOGdC4Q6KfAYrmmuicVyBk7YMJOMXTuQnIpZqReTiceibjdg/132, createdBy=2ab92087896, createdName=陈方郑, createdTime=Sun Dec 03 08:23:42 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-03 陈方郑

    学习好的好好的

    0

相关资讯

中国在帕金森治疗上与美国并肩:还可网络远程诊疗

中国网络科技的快速发展,让远在千里之外、身处异国的帕金森患者,在有WiFi或4G网络和一台电脑的情况下,就可以接受手术后远程诊疗。北京天坛医院功能神经外科主任张建国说,手术后远程诊疗,是中国治疗帕金森症其中一项创新功能,而更为关键的是,脑起搏器在中国国产化后价格的降低以及技术上的改进提升,让全球更多的帕金森患者有条件进行植入手术。“左侧大脑电压增加1伏,右脉宽加到70,频率不变。”北京天坛医院神经

JAMA Neurol:超声聚焦丘脑切开术可显著缓解药物难治性震颤型帕金森病症状

研究证实,对于震颤型帕金森病患者,接受超声聚焦丘脑切开术可显著缓解药物难治性震颤症状

JAMA Neurol:羟丁酸钠可改善帕金森患者白天过度嗜睡和夜间睡眠障碍

睡眠障碍紊乱是一种常见的帕金森非运动失调症状,治疗方案十分有限。近日研究人员考察了发作性嗜睡病一线用药--羟丁酸钠对帕金森患者白天过度嗜睡(EDS)和夜间睡眠睡眠障碍的疗效和安全性。本次IIa临床研究在瑞士进行。12名Epworth睡眠得分>10的PD患者参与。参与者随机接受羟丁酸钠或安慰剂,研究过程中1人因不良事件退出,11人完成最终研究。患者在睡前2.5-4小时服用3或9g药物,持续6周

Nat Chem Biol:百草枯可致帕金森症,却确证三个基因位点可抗氧化!

最近有一些药学研究者使用CRISPR-Cas9基因编辑系统确证了因使用百草枯(一种除草剂)而导致帕金森病发生的相关基因。并且发现了可以抵制药物毒性的三个基因。

Neurology:帕金森患者早期体重降低预示预后不良

研究发现,非典型帕金森综合征患者的体重降低速度快于帕金森病患者。帕金森病早期的显著体重降低预示着患者预后不良,因采取针对性的营养强化措施改善患者的长期预后

Neuron:帕金森病三十年来新突破!导致运动障碍的罪魁祸首或不是消失的多巴胺

近期发表在《细胞》子刊《神经元》杂志上的一项研究可能要颠覆这一传统认知了。来自韩国科学技术高级研究所(KAIST)和南洋理工大学的科学家发现,增加基底神经节的抑制信号,竟然会让丘脑更加兴奋,从而增加肌肉活动乃至震颤!这也就能解释,为什么很多患者吃了可以增加多巴胺水平的左旋多巴,反倒抖得更加厉害了。